Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Death/ICU 39% Death/ICU (b) 69% Lano et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 122 patients in France Lower mortality (p=0.28) and death/ICU (p=0.23), not stat. sig. Lano et al., Clinical Kidney J., 13:5, October 2.., doi:10.1093/ckj/sfaa199 Favors HCQ Favors control
Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort
Lano et al., Clinical Kidney Journal, 13:5, October 2020, 878–888, doi:10.1093/ckj/sfaa199
Lano et al., Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort, Clinical Kidney Journal, 13:5, October 2020, 878–888, doi:10.1093/ckj/sfaa199
Oct 2020   Source   PDF  
  All Studies   Meta
33% lower mortality with HCQ+AZ, p=0.28. Retrospective 122 French dialysis patients.
69% lower combined mortality/ICU, p=0.11, for the subgroup not requiring O2 on diagnosis (slightly earlier treatment).
risk of death, 33.1% lower, RR 0.67, p = 0.28, treatment 56, control 66, adjusted per study, odds ratio converted to relative risk.
risk of death/ICU, 38.9% lower, RR 0.61, p = 0.23, treatment 17 of 56 (30.4%), control 28 of 66 (42.4%), NNT 8.3, adjusted per study, odds ratio converted to relative risk.
risk of death/ICU, 68.7% lower, RR 0.31, p = 0.11, treatment 4 of 36 (11.1%), control 11 of 31 (35.5%), NNT 4.1, not requiring O2 on diagnosis (relatively early treatment).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lano et al., 21 Oct 2020, retrospective, France, peer-reviewed, median age 73.5, 30 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Clinical Kidney Journal, 2020, 878–888 doi: 10.1093/ckj/sfaa199 Original Article ORIGINAL ARTICLE Guillaume Lano1,2,*, Antoine Braconnier3,*, Stanislas Bataille 2,4, Guilhem Cavaille5, Julie Moussi-Frances5, Bertrand Gondouin1,6, Pascal Bindi7, Magued Nakhla8, Janette Mansour9, Pascale Halin10, Bénédicte Levy11, Eric Canivet12, Khaled Gaha3, Isabelle Kazes3, Natacha Noel3, Alain Wynckel3, Alexandre Debrumetz3, Noemie Jourde-Chiche 1,2, Valerie Moal1, Romain Vial1, Violaine Scarfoglière1, Mickael Bobot1,2, Marion Gully1, Tristan Legris1, Marion Pelletier1, Marion Sallee1,2, Stephane Burtey 1,2, Philippe Brunet1,2, Thomas Robert1 and Philippe Rieu3,13 1 Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France, 2Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France, 3Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France, 4Elsan, Phocean Institute of Nephrology, Clinique Bouchard, Marseille, France, 5 DIAVERUM, Saint Joseph Hospital, Marseille, France, 6Association des Dialysés Provence et Corse (ADPC), Marseille, France, 7Department of Nephrology, Verdun Hospital, Verdun, France, 8Department of Nephrology, Laon Hospital, Laon, France, 9Department of Nephrology, Soissons Hospital, Soissons, France, 10Department of Nephrology, Charleville-Mézières Hospital, Charleville-Mézières, France, 11Department of Nephrology, Troyes Hospital, Troyes, France, 12Association Régionale pour la Promotion de la Dialyse à Domicile (ARPDD), Reims, France and 13Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France *These authors contributed equally to this work. Correspondence to: Guillaume Lano; E-mail: Received: 29.6.2020; Editorial decision: 21.8.2020 C The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. V This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact 878 Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort Risk factors for critical COVID-19 in ESRD patients | 879 GRAPHICAL ABSTRACT Background. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD). Methods. We conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality. Results. Among the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop